Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first FDA approval for a prescription drug, scoring a nod for dry eye disease ...

Grab the top 3 stocks to buy right here. Alcon produces contact lenses, dry eye drops, gels and other related products. Tryptyr is a first-in-class TRPM8 receptor agonist (neuromodulator ...

yet less than 10% of diagnosed patients are being treated with a prescription product 4 "Today marks a tremendous milestone for Alcon as TRYPTYR becomes our first prescription pharmaceutical ...

Alcon Inc. (NYSE:ALC) has announced that the U.S. Food and Drug Administration (FDA) has approved TRYPTYR (acoltremon ophthalmic solution) 0.003% for the treatment of signs and symptoms of Dry Eye ...

That’s what happened to Alcon, the global eyecare company with manufacturing and research facilities in Berks County, when it reported first quarter core earnings per share missed the Zacks ...

Alcon (NYSE:ALC) shares fell 9% in premarket trading on Wednesday, after the Swiss-American pharmaceutical and medical device company missed estimates for quarterly earnings. The company also ...

Alcon reported quarterly earnings of 73 cents per share which missed the analyst consensus estimate of 75 cents per share. The company reported quarterly sales of $2.45 billion which missed the ...

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.

Alcon's management communicated confidence in the company's ability to deliver accelerated growth in the second half of 2025, driven by a robust pipeline of new product launches and strategic ...

On May 30, BTIG analysts reaffirmed their Buy rating and $99 price target for Alcon Inc. (NYSE:ALC) following the FDA’s approval of TRYPTYR for the treatment of dry eye disease (DED).

yet less than 10% of diagnosed patients are being treated with a prescription product 4 "Today marks a tremendous milestone for Alcon as TRYPTYR becomes our first prescription pharmaceutical treatment ...